These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Time-courses of plasma IL-6 and HMGB-1 reflect initial severity of clinical presentation but do not predict poor neurologic outcome following subarachnoid hemorrhage. Kiiski H; Långsjö J; Tenhunen J; Ala-Peijari M; Huhtala H; Hämäläinen M; Moilanen E; Öhman J; Peltola J eNeurologicalSci; 2017 Mar; 6():55-62. PubMed ID: 29260012 [TBL] [Abstract][Full Text] [Related]
8. Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial. Roelz R; Schubach F; Coenen VA; Jenkner C; Scheiwe C; Grauvogel J; Niesen WD; Urbach H; Taschner C; Seufert J; Kätzler J; Beck J; Reinacher PC Trials; 2021 Apr; 22(1):285. PubMed ID: 33858493 [TBL] [Abstract][Full Text] [Related]
9. Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke. Różański D; Szlufik S; Tomasiuk R; Milanowski Ł; Figura M; Saramak K; Myrcha P; Koziorowski D Brain Sci; 2021 Dec; 12(1):. PubMed ID: 35053782 [TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients. Timmermans K; Vaneker M; Scheffer GJ; Maassen P; Janssen S; Kox M; Pickkers P J Crit Care; 2015 Jun; 30(3):476-80. PubMed ID: 25721031 [TBL] [Abstract][Full Text] [Related]
11. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study. Oulhaj A; Alsuwaidi AR; Suliman A; Gasmelseed H; Khan S; Alawi S; Hukan Y; George J; Alshamsi F; Sheikh F; Babiker ZOE; Prattes J; Sourij H Int J Infect Dis; 2021 Jun; 107():188-194. PubMed ID: 33862208 [TBL] [Abstract][Full Text] [Related]
12. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit. El-Mekkawy MS; Saleh NY; Sonbol AA Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717 [TBL] [Abstract][Full Text] [Related]
14. Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator-associated pneumonia? Sunnetcioglu A; Sunnetcioglu M; Adıyaman F; Binici I; Soyoral L Clin Respir J; 2017 Nov; 11(6):925-930. PubMed ID: 26683264 [TBL] [Abstract][Full Text] [Related]
15. Associations between endothelin polymorphisms and aneurysmal subarachnoid hemorrhage, clinical vasospasm, delayed cerebral ischemia, and functional outcome. Griessenauer CJ; Starke RM; Foreman PM; Hendrix P; Harrigan MR; Fisher WS; Vyas NA; Lipsky RH; Lin M; Walters BC; Pittet JF; Mathru M J Neurosurg; 2018 May; 128(5):1311-1317. PubMed ID: 28548598 [TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986 [TBL] [Abstract][Full Text] [Related]